Hit enter to search or ESC to close
Home
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
Hepion Tackles NASH in P2 with Cyclophilin Inhibitor [Breaking Biotech]
By
Hepion
October 11, 2020
October 12th, 2020
Media Placements
,
Videos
No Comments
Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020
October 27, 2020
Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team
October 5, 2020
Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
September 29, 2020
Share
Tweet
Share
Pin
Home
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
